Viewing Study NCT06513234


Ignite Creation Date: 2025-12-25 @ 2:33 AM
Ignite Modification Date: 2026-03-01 @ 12:07 PM
Study NCT ID: NCT06513234
Status: RECRUITING
Last Update Posted: 2024-07-22
First Post: 2024-07-01
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module